Brief: Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026
08/12/2025 12:35
Dec 8 (Reuters) - Vaxcyte Inc PCVX.O: VAXCYTE DOSES FIRST PARTICIPANTS IN THE OPUS PHASE 3, NONINFERIORITY TRIAL EVALUATING VAX-31 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE AND PNEUMONIA IN ADULTS VAXCYTE INC - TOPLINE RESULTS FROM OPUS TRIAL EXPECTED IN Q4 2026 Source text: ID:nGNX2TF0sD Further company coverage: PCVX.O ((Reuters.Briefs@thomsonreuters.com;))